Adult Onset Still’s Disease (AOSD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

 Adult onset Still's Disease (AoSD) is a rare systemic autoinflammatory disease characterized by arthritis, spiking fever, skin rash, and elevated ferritin levels. Fever is a cardinal symptom in AoSD and occurs in 60 to 100% of cases. Patients typically report two fever spikes daily, one in the morning and one in the evening, usually >39 ◦C. In 60 to 80% of patients, a macular or maculopapular evanescent salmon-pink skin rash on the proximal limbs and trunk accompanies high fever. Arthralgia is the symptom that is observed in 70 to 100% of patients, often accompanied by polyarthritis involving small joints, imitating rheumatoid arthritis. Some patients with chronic articular AoSD show severe osteodestructive features, which cause ankyloses and functional disability. Leukopenia is related to an unfortunate course of disease with complications such as reactive haemophagocytic lymphohistiocytosis or thrombotic angiopathy.

·       The annual incidence rate ranges 0.21 to 0.63 in 100,000 population and the prevalence rate varies between 1.05 to 1. 34 per 100,000 populations. The most common findings were fever (97.6%), arthralgia (95.2%), arthritis (76.2%), rash (73.8%) and sore throat (40.5%).

Thelansis’s “Adult Onset Still’s Disease (AOSD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Adult Onset Still’s Disease (AOSD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Adult Onset Still’s Disease (AOSD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Adult Onset Still’s Disease (AOSD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Adult Onset Still’s Disease (AOSD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032